AMGN Hold: Symmetric risk-reward (10% down to $356 vs 9% up to $398) mandates neutrality with 10% tactical-add optionality on confirmed basing
Hold resolves through three binding constraints from prior AMGN decisions, with the 9/15 reflection providing decisive calibration. The 10% downside to $356 versus 9% upside to $398 is symmetric risk-reward (~1:1), not the "genuinely asymmetric" 17:6 the Aggressive analyst claims. The Aggressive analyst's scaling plan contradicts the technical report's identification of the Bollinger lower band at $363 — scaling into the worst entry zone in the chart. The Conservative analyst's fortress mentality (wait for sustained closes above $398) risks the 9/15 lesson's drift toward over-conservatism. The 200 SMA at $355.98 remains intact per the 9/11 reflection's binding constraint. Most likely scenario is sideways chop in $370-390 range where patient Hold generates modest alpha through dividend carry (2.68%), re-engagement optionality at $398, and catalyst optionality on MariTide Phase 3, Q3 earnings, Imdelltra filing, and olpasiran OCEAN(a).
| Position | Action |
|---|---|
| Current position level | Maintain current size (no trim, no add) |
| RSI divergence + price >$363 + MACD histogram contracting | Add 10% of position (capped per CAT 9/15 lesson, NOT Aggressive analyst's 25-33% at Bollinger lower band) |
| Confirmed close below $355.98 on volume (200 SMA break) | Trim 15-20% of position |
| Confirmed weekly close below $355.98 | Trim 25-33% additional (escalation) |
| Close >$398 on volume ≥1.5x 20-day average AND MACD histogram contracting from -9 toward zero | Re-engage with full position parameters |
| $355.98 close-based | Hard stop (exit position) |
| Close >$398 alone without MACD confirmation | AVOID adding |
| Scaling into $363-370 without RSI divergence | AVOID (knife-catching per 9/14 reflection) |
| Selling into weakness | AVOID |
| Protective puts | AVOID (overlap with existing stop = double-cost per 9/15 lesson) |
Amgen is a fundamentally mispriced defensive-growth biopharma trading at 15.4x forward P/E that suffered a 10% one-day selloff on news that doesn't apply to its pipeline, creating an asymmetric risk-reward opportunity with technical support at the 200 SMA.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $394.17 | bearish |
| 50 SMA | $398.15 | bearish |
| 200 SMA | $355.98 | neutral |
| RSI | 33.26 | bearish |
| MACD | –7.45 | bearish |
| MACD Signal | +1.03 | bearish |
| MACD Histogram | –8.48 | bearish |
| Bollinger Middle Band (20 SMA) | $418.81 | bearish |
| Bollinger Upper Band | $474.50 | bearish |
| Bollinger Lower Band | $363.11 | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: RSI divergence + price >$363 + MACD histogram contracting
Then: Add 10% of position
Price remains firmly above the 200 SMA, confirming the long-term structural uptrend is intact
↩ rebuts: “Bear use of short-term moving averages as bearish signals”
EV: +11.2% to +17.0% (target $418-$440 vs. entry $376) · concedes: Bear wins if Amgen closes below $363 on expanding volume and macro deteriorates further; Technical reclaim of $398 with volume is preferred confirmation before full position; MariTide represents binary optionality — upside is currently priced at near-zero; Short-term momentum (RSI 33.26, MACD -7.45) may not bottom immediately — snapback setup still building; 200 SMA support at $355.98 provides only 5.7% cushion before structural breakdown
AMGN is in a technical downtrend with distribution volume, expanded volatility, and multiple headwinds including class-level Lp(a) overhang, binary pipeline risk, high debt load in a tightening environment, and a dividend consuming 62% of FCF—offering unfavorable risk/reward at $376 with the 200 SMA only 5.7% below.
· concedes: Pelacarsen overreaction was 'overblown'—directionally correct but magnitude arguable; 51% EPS growth story is real IF the 5+ assumptions materialize; Imdelltra OS data is genuinely positive and 'real'; Technical failures (breaking 50 SMA on >2x volume) historically lead to 200 SMA tests—but this supports waiting for confirmation rather than buying now; Reddit silence may be 'consistent with defensive large-cap behavior' rather than bearish absence of buyers
→ vs conservative: Waiting for 'confirmation' at $398 or flush to $345-355 is market-neutral positioning dressed as risk management; fundamentals already confirmed the thesis, chart is lagging indicator
→ vs neutral: Trigger of 2.5M volume on close above $398 for half-position is too restrictive; by time AMGN reclaims $398 on volume, easy money is gone and you're chasing 6% higher
| ATR |
| 10.43 |
| neutral |
| 20-day VWMA | ~$405.75 | bearish |
| Latest Close | $376.35 | neutral |
Support: 374 · 363 · 356 · 345 | Resistance: 382 · 385 · 390 · 395 · 398 · 418
AMGN technical analysis showing a sharp reversal from highs near $445 to current $376.35, with the September 8th gap-down (–10% on 6.8M shares) confirming institutional distribution. Price is below all short and medium-term moving averages except the 200 SMA ($355.98), which remains the last major support line. Momentum is firmly bearish across RSI, MACD, and volume-weighted measures, while volatility has expanded with ATR at 10.43. Resistance clusters at $385–$398, with critical support at the Bollinger lower band ($363.11) and 200 SMA ($356).
Market Cap
$203.5B
P/E (TTM)
23.35x
Forward P/E
15.42x
PEG Ratio
2.30
P/B
17.41x
EPS (TTM)
$16.12
Forward EPS
$24.40
Implied EPS Growth
~51%
Dividend Yield
2.68%
Beta
0.426
52-Week Range
$269.77 – $447.03
50-Day MA
$399.43
200-Day MA
$359.78
Revenue TTM
$38.1B
Gross Profit
$27.4B
Gross Margin
71.9%
Operating Income TTM
$11.43B
Operating Margin
35.5%
EBITDA
$17.3B
Net Income TTM
$8.74B
Net Margin
22.95%
ROE
91.5%
ROA
8.67%
Total Assets
$95.6B
Total Equity
$11.7B
Total Debt
$57.3B
Net Debt
$43.3B
Cash and Equivalents
$14.0B
Current Ratio
1.37
Net Debt/EBITDA
~2.5x
Tangible Book Value
-$27.5B
Goodwill and Intangibles
$39.2B
FCF TTM
$8.65B
Annualized Dividends
~$5.4B
FCF/Dividend Coverage
1.6x
Q2 2026 Revenue
$10.05B
Q2 2026 Operating Income
$3.51B
Q2 2026 Net Income
$2.38B
Q2 2026 Diluted EPS
$4.37
Q2 2026 Operating Cash Flow
$4.0B
Q2 2026 CapEx
-$0.51B
Q2 2026 Free Cash Flow
$3.49B
Q2 2026 Dividends Paid
-$1.36B
Q1 2026 Revenue
$8.62B
Q4 2025 Revenue
$9.87B
Q3 2025 Revenue
$9.56B
Q2 2025 Revenue
$9.18B
Q3 2025 Net Income
$3.22B
Revenue Growth YoY
+9.5%
Operating Income Growth YoY
+32.3%
EPS Growth YoY
+64.9%
FCF Growth YoY
+82.6%
Debt/Equity Ratio
490%
Strengths
Concerns
Amgen is a large-cap biotech company with best-in-class profitability metrics (35.5% operating margin, 72% gross margin) and strong cash generation ($8.65B TTM FCF), trading at an attractive forward P/E of 15.42x with ~51% implied EPS growth. The stock offers defensive characteristics (beta 0.43) and a 2.68% dividend yield supported by 1.6x FCF coverage, while the company aggressively deleverages its $43.3B net debt post-Horizon acquisition. Key risks include elevated leverage, patent cliffs on legacy products (Enbrel, Neulasta), and pipeline execution requirements for MariTide to justify the growth narrative.
Macro: The Federal Reserve is actively tightening, not easing — Polymarket shows 95% probability of no rate cuts in 2026 (~$8.4M volume, +1.9pp WoW) and 64% probability of two Fed rate hikes (+40.5pp WoW), with 1 hike at 20% and 3 hikes at 16%. Global news confirms: Dow sank 600 points on Sept 16, S&P 500 and Nasdaq fell as Fed hiked rates and bond yields rose; 10-year Treasury below 5%. Recession risk is benign but creeping (10%, +3pp WoW). JPMorgan CEO Jamie Dimon: 'It's not clear to me we've slayed inflation' (Sept 16). This environment is a tailwind for established, dividend-paying pharma like AMGN even as growth/tech is de-rated.